211 related articles for article (PubMed ID: 25343945)
1. Population pharmacokinetic-pharmacodynamic modelling of 24-h diastolic ambulatory blood pressure changes mediated by axitinib in patients with metastatic renal cell carcinoma.
Chen Y; Rini BI; Bair AH; Mugundu GM; Pithavala YK
Clin Pharmacokinet; 2015 Apr; 54(4):397-407. PubMed ID: 25343945
[TBL] [Abstract][Full Text] [Related]
2. Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma.
Rini BI; Melichar B; Fishman MN; Oya M; Pithavala YK; Chen Y; Bair AH; Grünwald V
Ann Oncol; 2015 Jul; 26(7):1372-7. PubMed ID: 25701454
[TBL] [Abstract][Full Text] [Related]
3. Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.
Rini BI; Garrett M; Poland B; Dutcher JP; Rixe O; Wilding G; Stadler WM; Pithavala YK; Kim S; Tarazi J; Motzer RJ
J Clin Pharmacol; 2013 May; 53(5):491-504. PubMed ID: 23553560
[TBL] [Abstract][Full Text] [Related]
4. Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib.
Chen Y; Rini BI; Motzer RJ; Dutcher JP; Rixe O; Wilding G; Stadler WM; Tarazi J; Garrett M; Pithavala YK
Target Oncol; 2016 Apr; 11(2):229-34. PubMed ID: 26400730
[TBL] [Abstract][Full Text] [Related]
5. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial.
Rini BI; Melichar B; Ueda T; Grünwald V; Fishman MN; Arranz JA; Bair AH; Pithavala YK; Andrews GI; Pavlov D; Kim S; Jonasch E
Lancet Oncol; 2013 Nov; 14(12):1233-42. PubMed ID: 24140184
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic analysis of axitinib in healthy volunteers.
Garrett M; Poland B; Brennan M; Hee B; Pithavala YK; Amantea MA
Br J Clin Pharmacol; 2014 Mar; 77(3):480-92. PubMed ID: 23834452
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study.
Ravaud A; Gomez-Roca C; Picat MQ; Digue L; Chevreau C; Gimbert A; Chauzit E; Sitta R; Cornelis F; Asselineau J; Aziza R; Daste A; Quemener C; Baud J; Bikfalvi A; Pedenon-Périchout D; Doussau A; Molimard M; Delord JP
Eur J Cancer; 2017 Nov; 85():39-48. PubMed ID: 28886476
[TBL] [Abstract][Full Text] [Related]
8. Hemodialysis does not impact axitinib exposure: clinical case of a patient with metastatic renal cell carcinoma.
Thiery-Vuillemin A; Orillard E; Mouillet G; Calcagno F; Devillard N; Bouchet S; Royer B
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1273-1276. PubMed ID: 28451830
[TBL] [Abstract][Full Text] [Related]
9. A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients.
Schindler E; Amantea MA; Karlsson MO; Friberg LE
CPT Pharmacometrics Syst Pharmacol; 2017 Jun; 6(6):373-382. PubMed ID: 28378918
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of single-agent axitinib across multiple solid tumor types.
Tortorici MA; Cohen EE; Pithavala YK; Garrett M; Ruiz-Garcia A; Kim S; Fruehauf JP
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1279-89. PubMed ID: 25336084
[TBL] [Abstract][Full Text] [Related]
11. Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma.
Igarashi R; Inoue T; Fujiyama N; Tsuchiya N; Numakura K; Kagaya H; Saito M; Narita S; Satoh S; Niioka T; Miura M; Habuchi T
Med Oncol; 2018 Mar; 35(4):51. PubMed ID: 29524031
[TBL] [Abstract][Full Text] [Related]
12.
Scarpelli M; Bruce JY; Carmichael L; Eickhoff J; Kolesar J; Perlman S; Jeraj R; Liu G
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1245-1252. PubMed ID: 27817059
[TBL] [Abstract][Full Text] [Related]
13. Comparison of manual versus ambulatory blood pressure measurements with pharmacokinetic-pharmacodynamic modeling of antihypertensive compounds: application to moxonidine.
Trocóniz IF; de Alwis DP; Tillmann C; Callies S; Mitchell M; Schaefer HG
Clin Pharmacol Ther; 2000 Jul; 68(1):18-27. PubMed ID: 10945312
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma.
Rini BI; Escudier B; Hariharan S; Roberts WG; Tarazi J; Rosbrook B; Askerova Z; DeAnnuntis LL; Motzer RJ
Clin Genitourin Cancer; 2015 Dec; 13(6):540-7.e1-7. PubMed ID: 26320662
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with (18)F-3'deoxy-3'fluoro-L-thymidine positron emission tomography/computed tomography.
Bruce JY; Scully PC; Carmichael LL; Eickhoff JC; Perlman SB; Kolesar JM; Heideman JL; Jeraj R; Liu G
Cancer Chemother Pharmacol; 2015 Jul; 76(1):187-95. PubMed ID: 26021741
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacology of axitinib.
Chen Y; Tortorici MA; Garrett M; Hee B; Klamerus KJ; Pithavala YK
Clin Pharmacokinet; 2013 Sep; 52(9):713-25. PubMed ID: 23677771
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic-pharmacodynamic modeling of moxonidine using 24-hour ambulatory blood pressure measurements.
Hempel G; Karlsson MO; de Alwis DP; Toublanc N; McNay J; Schaefer HG
Clin Pharmacol Ther; 1998 Dec; 64(6):622-35. PubMed ID: 9871427
[TBL] [Abstract][Full Text] [Related]
18. Axitinib-induced proteinuria and efficacy in patients with metastatic renal cell carcinoma.
Nozawa M; Sugimoto K; Ohzeki T; Minami T; Shimizu N; Adomi S; Saito Y; Nose K; Yoshimura K; Uemura H
Int J Clin Oncol; 2016 Aug; 21(4):748-755. PubMed ID: 26694813
[TBL] [Abstract][Full Text] [Related]
19. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
[TBL] [Abstract][Full Text] [Related]
20. Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?
Goldstein R; Pickering L; Larkin J
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1545-57. PubMed ID: 20942625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
